The Peroxisome Proliferator-Activated Receptor-γ Agonist Pioglitazone Represses Inflammation in a Peroxisome Proliferator-Activated Receptor-α-Dependent Manner In Vitro and In Vivo in Mice

Journal of the American College of Cardiology

Volumn 52, Issue 10, 2008, Pages 869-881

  Orasanu, Gabriela ^a,c   Ziouzenkova, Ouliana ^a,c   Devchand, Pallavi R ^a,c   Nehra, Vedika ^a,c   Hamdy, Osama ^b,c   Horton, Edward S ^b,c   Plutzky, Jorge ^a,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b JOSLIN DIABETES CENTER   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

inflammation; PPAR; VCAM 1

Indexed keywords

GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; I KAPPA B ALPHA; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; PIRINIXIC ACID; ROSIGLITAZONE; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG RECEPTOR BINDING; ENDOTHELIUM CELL; FEMALE; GENE EXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; LIGAND BINDING; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; WILD TYPE;

ANIMALS; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; ENDOTHELINS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INFLAMMATION; MALE; MICE; MIDDLE AGED; PPAR ALPHA; PPAR GAMMA; THIAZOLIDINEDIONES; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR CELL ADHESION MOLECULE-1;

EID: 49849086021     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2008.04.055     Document Type: Article

References (91)

1. Glass C.K., and Witztum J.L. Atherosclerosis. The road ahead. Cell 104 (2001) 503-516
2. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 104 (2001) 365-372
3. Semenkovich C.F. Insulin resistance and atherosclerosis. J Clin Invest 116 (2006) 1813-1822
4. Brown J.D., and Plutzky J. Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets. Circulation 115 (2007) 518-533
5. Lindberg M., and Astrup A. The role of glitazones in management of type 2 diabetes. A dream or a nightmare?. Obes Rev 8 (2007) 381-384
6. Tontonoz P., Hu E., and Spiegelman B.M. Regulation of adipocyte gene expression and differentiation by peroxisome proliferator activated receptor gamma. Curr Opin Genet Dev 5 (1995) 571-576
7. Willson T.M., Cobb J.E., Cowan D.J., et al. The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones. J Med Chem 39 (1996) 665-668
8. Thomson PDR Healthcare. Physicians Desk Reference. 61st edition (2007), Thomson PDR Healthcare, Seattle, WA
9. Blaschke F., Caglayan E., and Hsueh W.A. Peroxisome proliferator-activated receptor gamma agonists: their role as vasoprotective agents in diabetes. Endocrinol Metab Clin North Am 35 (2006) 561-574
10. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 351 (2004) 1106-1118
11. Goldberg R.B., Kendall D.M., Deeg M.A., et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 28 (2005) 1547-1554
12. Nissen S.E., and Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356 (2007) 2457-2471
13. Lincoff A.M., Wolski K., Nicholls S.J., and Nissen S.E. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 298 (2007) 1180-1188
14. Singh S., Loke Y.K., and Furberg C.D. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 298 (2007) 1189-1195
15. Diamond G.A., Bax L., and Kaul S. Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death. Ann Intern Med 147 (2007) 578-581
16. Krall R.L. Cardiovascular safety of rosiglitazone. Lancet 369 (2007) 1995-1996
17. Dormandy J.A., Charbonnel B., Eckland D.J., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366 (2005) 1279-1289
18. Ahmed I., Furlong K., Flood J., Treat V.P., and Goldstein B.J. Dual PPAR- alpha/gamma agonists: promises and pitfalls in type 2 diabetes. Am J Ther 14 (2007) 49-62
19. Rubenstrunk A., Hanf R., Hum D.W., Fruchart J.C., and Staels B. Safety issues and prospects for future generations of PPAR modulators. Biochim Biophys Acta 177 (2007) 1065-1081
20. Galkina E., and Ley K. Vascular adhesion molecules in atherosclerosis. Arterioscler Thromb Vasc Biol 27 (2007) 2292-2301
21. Marx N., Sukhova G.K., Collins T., Libby P., and Plutzky J. PPAR-alpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation 99 (1999) 3125-3131
22. Ziouzenkova O., Perrey S., Marx N., Bacqueville D., and Plutzky J. Peroxisome proliferator-activated receptors. Curr Atheroscler Rep 4 (2002) 59-64
23. Lee S.S., and Gonzalez F.J. Targeted disruption of the peroxisome proliferator-activated receptor alpha gene, PPAR alpha. Ann N Y Acad Sci 804 (1996) 524-529
24. Hamdy O., Ledbury S., Mullooly C., et al. Lifestyle modification improves endothelial function in obese subjects with the insulin resistance syndrome. Diabetes Care 26 (2003) 2119-2125
25. Grundy S.M., Cleeman J.I., Merz C.N., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. J Am Coll Cardiol 44 (2004) 720-732
26. Tseng K.H. Standards of medical care in diabetes-2006. Diabetes Care 29 Suppl 1 (2006) S4-S42
27. Ziouzenkova O., Perrey S., Asatryan L., et al. Lipolysis of triglyceride-rich lipoproteins generates PPAR ligands: evidence for an antiinflammatory role for lipoprotein lipase. Proc Natl Acad Sci U S A 100 (2003) 2730-2735
28. Ahmed W., Orasanu G., Nehra V., et al. High-density lipoprotein hydrolysis by endothelial lipase activates PPAR-alpha: a candidate mechanism for high-density lipoprotein-mediated repression of leukocyte adhesion. Circ Res 98 (2006) 490-498
29. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 26 (2003) S5-S20
30. Eckland D., and Danhof M. Clinical pharmacokinetics of pioglitazone. Exp Clin Endocrinol Diabetes 108 Suppl 2 (2000) S234-S242
31. Jackson S.M., Parhami F., Xi X.P., et al. Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction. Arterioscler Thromb Vasc Biol 19 (1999) 2094-2104
32. Li A.C., Brown K.K., Silvestre M.J., Willson T.M., Palinski W., and Glass C.K. Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J Clin Invest 106 (2000) 523-531
33. Rival Y., Beneteau N., Taillandier T., et al. PPAR-alpha and PPAR-delta activators inhibit cytokine-induced nuclear translocation of NF-kappaB and expression of VCAM-1 in EAhy926 endothelial cells. Eur J Pharmacol 435 (2002) 143-151
34. Dreyer C., Krey G., Keller H., Givel F., Helftenbein G., and Wahli W. Control of the peroxisomal beta-oxidation pathway by a novel family of nuclear hormone receptors. Cell 68 (1992) 879-887
35. Delerive P., Gervois P., Fruchart J.C., and Staels B. Induction of IkappaBalpha expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor-alpha activators. J Biol Chem 275 (2000) 36703-36707
36. Sakamoto J., Kimura H., Moriyama S., et al. Activation of human peroxisome proliferator-activated receptor (PPAR-) subtypes by pioglitazone. Biochem Biophys Res Commun 278 (2000) 704-711
37. Ryan K.E., McCance D.R., Powell L., McMahon R., and Trimble E.R. Fenofibrate and pioglitazone improve endothelial function and reduce arterial stiffness in obese glucose tolerant men. Atherosclerosis 194 (2007) e123-e130
38. Takase H., Nakazawa A., Yamashita S., et al. Pioglitazone produces rapid and persistent reduction of vascular inflammation in patients with hypertension and type 2 diabetes mellitus who are receiving angiotensin II receptor blockers. Metabolism 56 (2007) 559-564
39. Gao J., Ann Garulacan L., Storm S.M., et al. Identification of in vitro protein biomarkers of idiosyncratic liver toxicity. Toxicol In Vitro 18 (2004) 533-541
40. Bottoni P., Giardina B., Martorana G.E., et al. A two-dimensional electrophoresis preliminary approach to human hepatocarcinoma differentiation induced by PPAR-agonists. J Cell Mol Med 9 (2005) 462-467
41. Guo L., Zhang L., Sun Y., et al. Differences in hepatotoxicity and gene expression profiles by anti-diabetic PPAR gamma agonists on rat primary hepatocytes and human HepG2 cells. Mol Divers 10 (2006) 349-360
42. Johnson M.D., Campbell L.K., and Campbell R.K. Troglitazone: review and assessment of its role in the treatment of patients with impaired glucose tolerance and diabetes mellitus. Ann Pharmacother 32 (1998) 337-348
43. Chiquette E., Ramirez G., and Defronzo R. A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med 164 (2004) 2097-2104
44. Bogacka I., Xie H., Bray G.A., and Smith S.R. The effect of pioglitazone on peroxisome proliferator-activated receptor-gamma target genes related to lipid storage in vivo. Diabetes Care 27 (2004) 1660-1667
45. Plutzky J. Peroxisome proliferator-activated receptors in endothelial cell biology. Curr Opin Lipidol 12 (2001) 511-518
46. Haffner S.M., Greenberg A.S., Weston W.M., Chen H., Williams K., and Freed M.I. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 106 (2002) 679-684
47. Sidhu J.S., Cowan D., and Kaski J.C. The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients. J Am Coll Cardiol 42 (2003) 1757-1763
48. Plutzky J. Peroxisome proliferator-activated receptors as therapeutic targets in inflammation. J Am Coll Cardiol 42 (2003) 1764-1766
49. Yoshimoto T., Naruse M., Shizume H., et al. Vasculo-protective effects of insulin sensitizing agent pioglitazone in neointimal thickening and hypertensive vascular hypertrophy. Atherosclerosis 145 (1999) 333-340
50. Koshiyama H., Shimono D., Kuwamura N., Minamikawa J., and Nakamura Y. Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 86 (2001) 3452-3456
51. Sidhu J.S., Kaposzta Z., Markus H.S., and Kaski J.C. Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus. Arterioscler Thromb Vasc Biol 24 (2004) 930-934
52. Mazzone T., Meyer P.M., Feinstein S.B., et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA 296 (2006) 2572-2581
53. Hedblad B., Zambanini A., Nilsson P., Janzon L., and Berglund G. Rosiglitazone and carotid IMT progression rate in a mixed cohort of patients with type 2 diabetes and the insulin resistance syndrome: main results from the Rosiglitazone Atherosclerosis study. J Intern Med 261 (2007) 293-305
54. Dandona P., Aljada A., and Chaudhuri A. Vascular reactivity and thiazolidinediones. Am J Med 115 (2003) 81S-86S
55. Lago R.M., Singh P.P., and Nesto R.W. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet 370 (2007) 1129-1136
56. Nissen S.E., Nicholls S.J., Wolski K., et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 299 (2008) 1561-1573
57. Dierkes J., Westphal S., and Luley C. Serum homocysteine increases after therapy with fenofibrate or bezafibrate. Lancet 554 (1999) 219-220
58. Lipscombe J., Lewis G.F., Cattran D., and Bargman J.M. Deterioration in renal function associated with fibrate therapy. Clin Nephrol 55 (2001) 39-44
59. Luc G., Jacob N., Bouly M., Fruchart J.C., Staels B., and Giral P. Fenofibrate increases homocystinemia through a PPAR-alpha-mediated mechanism. J Cardiovasc Pharmacol 43 (2004) 452-453
60. Davidson M.H., Armani A., McKenney J.M., and Jacobson T.A. Safety considerations with fibrate therapy. Am J Cardiol 99 (2007) 3C-18C
61. Rubins H.B., Robins S.J., Collins D., et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 341 (1999) 410-418
62. Keech A., Simes R.J., Barter P., et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366 (2005) 1849-1861
63. Mulvihill N.T., Foley J.B., Crean P., and Walsh M. Prediction of cardiovascular risk using soluble cell adhesion molecules. Eur Heart J 23 (2002) 1569-1574
64. Abe Y., El-Masri B., Kimball K.T., et al. Soluble cell adhesion molecules in hypertriglyceridemia and potential significance on monocyte adhesion. Arterioscler Thromb Vasc Biol 18 (1998) 723-731
65. Calabresi L., Gomaraschi M., Villa B., Omoboni L., Dmitrieff C., and Franceschini G. Elevated soluble cellular adhesion molecules in subjects with low HDL-cholesterol. Arterioscler Thromb Vasc Biol 22 (2002) 656-661
66. Pineda Torra I., Gervois P., and Staels B. Peroxisome proliferator-activated receptor alpha in metabolic disease, inflammation, atherosclerosis and aging. Curr Opin Lipidol 10 (1999) 151-159
67. Sethi S., Ziouzenkova O., Ni H., Wagner D.D., Plutzky J., and Mayadas T.N. Oxidized omega-3 fatty acids in fish oil inhibit leukocyte-endothelial interactions through activation of PPAR-alpha. Blood 100 (2002) 1340-1346
68. Okapcova J., and Gabor D. The levels of soluble adhesion molecules in diabetic and nondiabetic patients with combined hyperlipoproteinemia and the effect of ciprofibrate therapy. Angiology 55 (2004) 629-639
69. Xu X., Otsuki M., Saito H., et al. PPAR-alpha and GR differentially down-regulate the expression of nuclear factor-kappaB-responsive genes in vascular endothelial cells. Endocrinology 142 (2001) 3332-3339
70. Blankenberg S., Barbaux S., and Tiret L. Adhesion molecules and atherosclerosis. Atherosclerosis 170 (2003) 191-203
71. Rossi A., Kapahi P., Natoli G., et al. Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IkappaB kinase. Nature 403 (2000) 103-108
72. Ward C., Dransfield I., Murray J., Farrow S.N., Haslett C., and Rossi A.G. Prostaglandin D2 and its metabolites induce caspase-dependent granulocyte apoptosis that is mediated via inhibition of I kappa B alpha degradation using a peroxisome proliferator-activated receptor-gamma-independent mechanism. J Immunol 168 (2002) 6232-6243
73. Guyton K., Bond R., Reilly C., Gilkeson G., Halushka P., and Cook J. Differential effects of 15-deoxy-delta(12,14)-prostaglandin J2 and a peroxisome proliferator-activated receptor gamma agonist on macrophage activation. J Leukoc Biol 69 (2001) 631-638
74. Mohanty P., Aljada A., Ghanim H., et al. Evidence for a potent antiinflammatory effect of rosiglitazone. J Clin Endocrinol Metab 89 (2004) 2728-2735
75. Klotz L., Schmidt M., Giese T., et al. Proinflammatory stimulation and pioglitazone treatment regulate peroxisome proliferator-activated receptor gamma levels in peripheral blood mononuclear cells from healthy controls and multiple sclerosis patients. J Immunol 175 (2005) 4948-4955
76. Willson T.M., Brown P.J., Sternbach D.D., and Henke B.R. The PPARs: from orphan receptors to drug discovery. J Med Chem (2000) 527-550
77. Pascual G., Fong A.L., Ogawa S., et al. A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma. Nature 437 (2005) 759-763
78. Ghisletti S., Huang W., Ogawa S., et al. Parallel SUMOylation-dependent pathways mediate gene- and signal-specific transrepression by LXRs and PPAR-gamma. Mol Cell 25 (2007) 57-70
79. Dutertre M., and Smith C.L. Molecular mechanisms of selective estrogen receptor modulator (SERM) action. J Pharmacol Exp Ther 295 (2000) 431-437
80. Fievet C., Fruchart J.C., and Staels B. PPAR-alpha and PPAR-gamma dual agonists for the treatment of type 2 diabetes and the metabolic syndrome. Curr Opin Pharmacol 6 (2006) 606-614
81. Knouff C., and Auwerx J. Peroxisome proliferator-activated receptor-gamma calls for activation in moderation: lessons from genetics and pharmacology. Endocr Rev 25 (2004) 899-918
82. Seimandi M., Lemaire G., Pillon A., et al. Differential responses of PPARalpha, PPARdelta, and PPARgamma reporter cell lines to selective PPAR synthetic ligands. Anal Biochem 344 (2005) 8-15
83. Hamuro Y., Coales S.J., Morrow J.A., et al. Hydrogen/deuterium-exchange (H/D-Ex) of PPAR-gamma LBD in the presence of various modulators. Protein Sci 15 (2006) 1883-1892
84. Henke B.R. Peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes. J Med Chem 47 (2004) 4118-4127
85. Nissen S.E., Wolski K., and Topol E.J. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA 294 (2005) 2581-2586
86. Hellmold H., Zhang H., Andersson U., et al. Tesaglitazar, a PPAR-alpha/gamma agonist, induces interstitial mesenchymal cell DNA synthesis and fibrosarcomas in subcutaneous tissues in rats. Toxicol Sci 98 (2007) 63-74
87. Lin Z.J., Ji W., Desai-Krieger D., and Shum L. Simultaneous determination of pioglitazone and its two active metabolites in human plasma by LC-MS/MS. J Pharm Biomed Anal 33 (2003) 101-108
88. Shen Z., Reed J.R., Creighton M., et al. Identification of novel metabolites of pioglitazone in rat and dog. Xenobiotica 33 (2003) 499-509
89. Wang X.L., McCredie R.M., and Wilcken D.E. Common DNA polymorphisms at the lipoprotein lipase gene. Association with severity of coronary artery disease and diabetes. Circulation 96 (1996) 1339-1345
90. Nagashima K., Lopez C., Donovan D., et al. Effects of the PPAR-gamma agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus. J Clin Invest 115 (2005) 1323-1332
91. Staels B., Vu-Dac N., Kosykh V.A., et al. Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates. J Clin Invest 95 (1995) 705-712